Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House members push for CT Colonography NCD

This article was originally published in The Gray Sheet

Executive Summary

Six House members, led by Rep. Barbara Cubin, R-Wyo., want CMS to approve a national coverage determination for computed tomography colonography as a screening test for colorectal cancer - a proposal that the agency will be taking up at a Medicare Evidence Development & Coverage Advisory Committee meeting on Nov. 19 ("1The Gray Sheet" Nov. 3, 2008, p. 10). Cubin, along with Reps. Ed Towns, D-N.Y., Chip Pickering, R-Miss., Charlie Wilson, D-Ohio, John Sullivan, R-Okla., and Tammy Baldwin, D-Wis., told CMS in an Oct. 24 letter that allowing CTC, also known as "virtual colonoscopy," to be covered under an NCD would provide a cheaper alternative to traditional optical colonoscopies for patients and would result in more patients getting screened for cancer

You may also be interested in...

MedCAC To Ponder Cost Question At Virtual Colonoscopy Meeting

CMS wants an advisory board to consider the costs per life years saved for computed tomography colonography at a Nov. 19 meeting

Stockwatch: Coronavirus Takes A Bite Out Of AstraZeneca’s Guidance, GSK and AbbVie Get Spinning

The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off? 

Gemme Bemoans ‘State Of Emergency’ In France

French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts